|
1
|
Ker CG, Chen HY, Chen KS, et al: Clinical
significance of cell differentiation in hepatocellular carcinoma.
Hepatogastroenterology. 50:475–479. 2003.PubMed/NCBI
|
|
2
|
Nowak D, Stewart D and Koeffler HP:
Differentiation therapy of leukemia: 3 decades of development.
Blood. 113:3655–3665. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang L, Sun H, Zhao F, et al: BMP4
administration induces differentiation of CD133+ hepatic
cancer stem cells, blocking their contributions to hepatocellular
carcinoma. Cancer Res. 72:4276–4285. 2012.PubMed/NCBI
|
|
4
|
Yin C, Lin Y, Zhang X, et al:
Differentiation therapy of hepatocellular carcinoma in mice with
recombinant adenovirus carrying hepatocyte nuclear factor-4alpha
gene. Hepatology. 48:1528–1539. 2008. View Article : Google Scholar
|
|
5
|
Ishiyama T, Kano J, Minami Y, Iijima T,
Morishita Y and Noguchi M: Expression of HNFs and C/EBP alpha is
correlated with immunocytochemical differentiation of cell lines
derived from human hepatocellular carcinomas, hepatoblastomas and
immortalized hepatocytes. Cancer Sci. 94:757–763. 2003. View Article : Google Scholar
|
|
6
|
Costa RH, Kalinichenko VV, Holterman AX
and Wang X: Transcription factors in liver development,
differentiation, and regeneration. Hepatology. 38:1331–1347. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
DeLaForest A, Nagaoka M, Si-Tayeb K, et
al: HNF4A is essential for specification of hepatic progenitors
from human pluripotent stem cells. Development. 138:4143–4153.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walesky C, Edwards G, Borude P, et al:
Hepatocyte nuclear factor 4 alpha deletion promotes
diethylnitrosamine-induced hepatocellular carcinoma in mice.
Hepatology. 57:2480–2490. 2013. View Article : Google Scholar
|
|
9
|
Ning BF, Ding J, Yin C, et al: Hepatocyte
nuclear factor 4 alpha suppresses the development of hepatocellular
carcinoma. Cancer Res. 70:7640–7651. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Balabanian K, Lagane B, Infantino S, et
al: The chemokine SDF-1/CXCL12 binds to and signals through the
orphan receptor RDC1 in T lymphocytes. J Biol Chem.
280:35760–35766. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burns JM, Summers BC, Wang Y, et al: A
novel chemokine receptor for SDF-1 and I-TAC involved in cell
survival, cell adhesion, and tumor development. J Exp Med.
203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rajagopal S, Kim J, Ahn S, et al:
Beta-arrestin - but not G protein-mediated signaling by the ‘decoy’
receptor CXCR7. Proc Natl Acad Sci USA. 107:628–632. 2010.
|
|
13
|
Yu S, Crawford D, Tsuchihashi T, Behrens
TW and Srivastava D: The chemokine receptor CXCR7 functions to
regulate cardiac valve remodeling. Dev Dyn. 240:384–393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maksym RB, Tarnowski M, Grymula K, et al:
The role of stromal-derived factor-1-CXCR7 axis in development and
cancer. Eur J Pharmacol. 625:31–40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xue TC, Chen RX, Han D, et al:
Down-regulation of CXCR7 inhibits the growth and lung metastasis of
human hepatocellular carcinoma cells with highly metastatic
potential. Exp Ther Med. 3:117–123. 2012.PubMed/NCBI
|
|
16
|
Xue TC, Chen RX, Ren ZG, Zou JH, Tang ZY
and Ye SL: Transmembrane receptor CXCR7 increases the risk of
extrahepatic metastasis of relatively well-differentiated
hepatocellular carcinoma through upregulation of osteopontin. Oncol
Rep. 30:105–110. 2013.
|
|
17
|
Pasini D, Bracken AP, Hansen JB, Capillo M
and Helin K: The polycomb group protein Suz12 is required for
embryonic stem cell differentiation. Mol Cell Biol. 27:3769–3779.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dalby B, Cates S, Harris A, et al:
Advanced transfection with Lipofectamine 2000 reagent: primary
neurons, siRNA, and high-throughput applications. Methods.
33:95–103. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun HC, Zhuang PY, Qin LX, et al:
Incidence and prognostic values of lymph node metastasis in
operable hepatocellular carcinoma and evaluation of routine
complete lymphadenectomy. J Surg Oncol. 96:37–45. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Simon R, Mirlacher M and Sauter G:
Immunohistochemical analysis of tissue microarrays. Methods Mol
Biol. 664:113–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lugli A, Spichtin H, Maurer R, et al:
EphB2 expression across 138 human tumor types in a tissue
microarray: high levels of expression in gastrointestinal cancers.
Clin Cancer Res. 11:6450–6458. 2005. View Article : Google Scholar
|
|
22
|
Liu LL, Fu D, Ma Y and Shen XZ: The power
and the promise of liver cancer stem cell markers. Stem Cells Dev.
20:2023–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee TK, Castilho A, Cheung VC, Tang KH, Ma
S and Ng IO: CD24(+) liver tumor-initiating cells drive
self-renewal and tumor initiation through STAT3-mediated NANOG
regulation. Cell Stem Cell. 9:50–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang ZF, Ho DW, Ng MN, et al: Significance
of CD90+ cancer stem cells in human liver cancer. Cancer
Cell. 13:153–166. 2008.
|
|
25
|
Yamashita T, Honda M, Nio K, et al:
Oncostatin m renders epithelial cell adhesion molecule-positive
liver cancer stem cells sensitive to 5- Fluorouracil by inducing
hepatocytic differentiation. Cancer Res. 70:4687–4697. 2010.
View Article : Google Scholar
|
|
26
|
Hay DC, Zhao D, Fletcher J, et al:
Efficient differentiation of hepatocytes from human embryonic stem
cells exhibiting markers recapitulating liver development in vivo.
Stem Cells. 26:894–902. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hatzis P, Kyrmizi I and Talianidis I:
Mitogen-activated protein kinase-mediated disruption of
enhancer-promoter communication inhibits hepatocyte nuclear factor
4alpha expression. Mol Cell Biol. 26:7017–7029. 2006. View Article : Google Scholar
|
|
28
|
Zhao Z, Hong W, Zeng Z, et al:
Mucroporin-M1 inhibits hepatitis B virus replication by activating
the mitogen-activated protein kinase (MAPK) pathway and
down-regulating HNF4alpha in vitro and in vivo. J Biol Chem.
287:30181–30190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shenoy SK and Lefkowitz RJ:
β-Arrestin-mediated receptor trafficking and signal transduction.
Trends Pharmacol Sci. 32:521–533. 2011.
|
|
30
|
Basson MA: Signaling in cell
differentiation and morphogenesis. Cold Spring Harb Perspect Biol.
4:2012.pii: a008151. View Article : Google Scholar
|
|
31
|
Yokoyama A, Katsura S, Ito R, et al:
Multiple post-translational modifications in hepatocyte nuclear
factor 4α. Biochem Biophys Res Commun. 410:749–753. 2011.
|
|
32
|
Hanse EA, Mashek DG, Becker JR, et al:
Cyclin D1 inhibits hepatic lipogenesis via repression of
carbohydrate response element binding protein and hepatocyte
nuclear factor 4α. Cell Cycle. 11:2681–2690. 2012.PubMed/NCBI
|
|
33
|
Sakamaki J, Daitoku H, Kaneko Y, Hagiwara
A, Ueno K and Fukamizu A: GSK3β regulates gluconeogenic gene
expression through HNF4α and FOXO1. J Recept Signal Transduct Res.
32:96–101. 2012.
|
|
34
|
Cozzolino AM, Alonzi T, Santangelo L, et
al: TGFβ overrides HNF4α tumor suppressing activity through GSK3β
inactivation: implication for hepatocellular carcinoma gene
therapy. J Hepatol. 58:65–72. 2013.
|
|
35
|
Colletti M, Cicchini C, Conigliaro A, et
al: Convergence of Wnt signaling on the HNF4alpha-driven
transcription in controlling liver zonation. Gastroenterology.
137:660–672. 2009. View Article : Google Scholar : PubMed/NCBI
|
